Drug Profile
Research programme: virus-like particle immunotherapies - Angany Genetics
Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator ANGANY Genetics
- Class Allergy immunotherapies; Virus-like particle vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Allergy(Prevention) in France
- 03 Mar 2017 Preclinical trials in Hypersensitivity in France before March 2017